title: Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study.
abstract: In a randomised multicentre study, the prophylactic efficacy of lithium and carbamazepine was compared in schizoaffective disorder. A total of 90 ICD-9 schizoaffective patients were included in the maintenance phase (2.5 years). They were also diagnosed according to RDC and DSM-III-R and classified into subgroups. Mean serum levels were 0.58 +/- 0.12 mmol/l for lithium and 6.4 +/- 1.5 micrograms/ml for carbamazepine (mean dose 643 +/- 179 mg/d). Outcome criteria were hospitalisation, recurrence, concomitant psychotropic medication and adverse effects leading to discontinuation. There were more non-completers under carbamazepine than under lithium (p = 0.02). Survival analyses demonstrated no significant differences between lithium and carbamazepine in treatment outcome. Patient's ratings of side effects (p = 0.003) and treatment satisfaction (p = 0.02) favoured carbamazepine. Following the RDC criteria, patients of the schizodepressive and non-classifiable type did better under carbamazepine (p = 0.055 for recurrence), whereas in the schizomanic patients equipotency of both drugs was found. Applying DSM-III-R, carbamazepine demonstrated a superiority in the patient group with more schizophrenia-like or depressive disorders (p = 0.040 for recurrence), but not in patients fulfilling the DSM-III-R criteria of bipolar disorder. Lithium and carbamazepine seem to be equipotent alternatives in the maintenance treatment of broadly defined schizoaffective disorders. However, in subgroups with depressive or schizophrenia-like features and regarding its long-term tolerability carbamazepine seems to be superior.
authors.affiliation: Psychiatric Hospital of the University of Munich, Germany. wgreil@psy.med.uni-muenchen.de
authors.forename: W
authors.initials: W
authors.lastname: Greil
authors.forename: W
authors.initials: W
authors.lastname: Ludwig-Mayerhofer
authors.forename: N
authors.initials: N
authors.lastname: Erazo
authors.forename: R R
authors.initials: RR
authors.lastname: Engel
authors.forename: A
authors.initials: A
authors.lastname: Czernik
authors.forename: H
authors.initials: H
authors.lastname: Giedke
authors.forename: B
authors.initials: B
authors.lastname: Müller-Oerlinghausen
authors.forename: M
authors.initials: M
authors.lastname: Osterheider
authors.forename: G A
authors.initials: GA
authors.lastname: Rudolf
authors.forename: H
authors.initials: H
authors.lastname: Sauer
authors.forename: J
authors.initials: J
authors.lastname: Tegeler
authors.forename: T
authors.initials: T
authors.lastname: Wetterling
mesh_terms: D000328:Adult; D018692:Antimanic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002220:Carbamazepine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016651:Lithium Carbonate / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010359:Patient Readmission / Q000706:statistics & numerical data; D017060:Patient Satisfaction; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D018692:Antimanic Agents; D016651:Lithium Carbonate; D002220:Carbamazepine